Antigenics Inc. (New York)'s Oncophage(R) Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer

ANAHEIM, Calif.--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) today announced additional follow-up data on the company’s Phase 3 investigational therapeutic cancer vaccine Oncophage® (vitespen). The end-of-study results, which reflect an additional 17 months’ data collection, showed that in a substantial subset of patients (n = 362) at intermediate risk for disease recurrence, Oncophage demonstrated a clinically significant improvement in recurrence-free survival (RFS) of approximately 45 percent (P < 0.01; hazard ratio [HR] = 0.55). In addition, updated analysis in this group of patients revealed a new potential benefit associated with Oncophage treatment: for intermediate-risk patients there was a trend towards improved overall survival, the study’s secondary endpoint. Furthermore, the positive overall survival trend observed to date correlates with the RFS improvement demonstrated in previous analyses. This is the largest, randomized Phase 3 kidney cancer trial ever completed in the adjuvant treatment setting.

Back to news